FRM
VYGR icon

Fox Run Management’s Voyager Therapeutics VYGR Stock Holding History

Fox Run Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,159
Closed -$96.2K – 1128
2024
Q2 		$96.2K Buy
+12,159
New +$102K 0.02% 724

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fox Run Management's VYGR Position: Q3 2024 in Review

Fox Run Management sold out of Voyager Therapeutics (VYGR) in Q3 2024, closing a stake of 12,159 shares — an estimated $96.2K sold.

Fox Run Management first reported a position in VYGR in Q2 2024 and held it in 1 quarter. The position peaked at $96.2K in Q2 2024. 128 funds tracked by Wall St. Rank hold VYGR as of Q3 2024.

  • Fox Run Management reported no remaining Voyager Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Fox Run Management sold 12,159 Voyager Therapeutics shares in Q3 2024, an estimated $96.2K.
  • Fox Run Management first reported a position in Voyager Therapeutics in Q2 2024 and held it in 1 quarter.
  • Fox Run Management's Voyager Therapeutics position peaked at $96.2K in Q2 2024.
  • 128 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2024.

Based on Fox Run Management's 13F filing for Q3 2024, filed 12 Nov 2024.